Ruti Aga: Six Years, a Forged Prescription and a Drug-Class Error

The clinic that issued the prescription existed on paper and nowhere else. The person who signed it held no medical registration — he was a member of Ruti Aga's own family. When the Athletics Integrity Unit (AIU) asked the clinic about the document, the answer came back that no such old prescription pad had ever been kept there. Three verifications ran. All three failed.

The AIU statement issued on Thursday carried two numbers — two years, and four years. The sum is six. The ban is dated from 10 September, the same date her provisional suspension began. The statement does not name the year, so neither will I.

The race she was caught in has no recorded mark. A half marathon in China in March, which she won. No time, no field strength, no splits, no sector times. I went looking for the result and came back with a longer testimony from the silence.

Context: one name, one title, one date

Ruti Aga, 32, Ethiopian marathoner. The record shows the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors. Going by public race lists, she was second in Berlin 2026 in roughly 2:18:34 and won Tokyo 2026 in roughly 2:20:40. Those figures do not come from the AIU statement. I am using them as context, not as verified fact — and that distinction is the subject of this entire story.

The March race was in China, which means a World Athletics Label road race, which means in-competition testing. A road race's testing window opens at 23:59 the night before the gun. That technical detail will matter, because this case turns on the day of the race, not the month.

In years of reading entry lists and results sheets from road races, one pattern holds: an Indian race gets start-list coverage and no results sheet. A Chinese race with a Kenyan-Ethiopian elite field gets the reverse — the result is logged, the medical paperwork never is. Aga's case emerged from that exact gap.

Core: the drug class, and one error that killed a defence

The source report calls methylprednisolone a "prohibited steroid" and states it is classed as performance enhancing by WADA. That is imprecise and misleading. Methylprednisolone is not an anabolic steroid (WADA class S1); it is a glucocorticoid (class S9) — and under the current List, S9 glucocorticoids are prohibited in-competition only, by injection, oral or rectal route. A methylprednisolone injection into the knee is entirely legal out of competition. The same injection becomes a violation if it leaves residues in a sample on race day.

So the legal hinge here is route and timing, not the substance. And that is precisely where Aga had a defence. Intra-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners; it is not a hidden cheat, it is a clinic's ordinary line. With genuine medical records, the medical justification, the route and the washout calculation would all have stood on paper. A defence was available. It was not built. It was fabricated.

There is another layer. The injury explanation is technically plausible, and the plausibility is what makes it fatal. An athlete with real treatment fights with a real file. An athlete who forges a prescription burns her own strongest argument. At the AIU, the two years did not become a six-year case through the drug; they became one through four years for tampering — the matter is not the race but the changeover nobody films, the one from injection to sample.

The arithmetic is clean. Two years for the presence violation — the standard shape of a Specified Substance finding where intent is not proven. Four years for tampering — the Code's default. The sum is six. One thing follows that the statement does not spell out: the panel rejected the no-significant-fault reduction that would otherwise have cut the presence sanction. Dating the ban from 10 September is no concession; provisional suspension time counts anyway. In real terms the athlete gained nothing.

Core: where the money is, and where the doctor is not

China's label-race circuit is the income tier between Majors for East African marathoners — decent appearance fees, limited competition, low risk. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races, and the bill always lands on the athlete's account.

Injury is the first part of that equation. Chronic knee pathology is a familiar failure mode in high-mileage marathoners. The second part is that the pressure to mask injury is financial — if you do not look in form, the appearance fee walks. The third part: the cheapest, most available tool for hiding pain is a glucocorticoid. The fourth part is what the statement leaves out — there was no credentialed team physician around her. The "doctor" was a family member who claimed to have used an old prescription pad from a former workplace, and that workplace did not exist.

The AIU statement names only the family member. Whether an agent or management was investigated is not public — and that is the largest unanswered question in the file. An athlete does not arrive at a forged prescription alone; someone advises it, someone accepts it, someone puts it in front of the AIU. Where money flows into appearance fees and not into medical governance, that chain assembles itself.

The career arithmetic is blunt. Age 32, a six-year ban, a return at roughly 38. Ethiopian women's marathon depth is such that a 2:18 performer is not automatically selectable; a 38-year-old returning with a doping record entering selection conversation is hard to imagine. Her absence has no measurable effect on the national team's medal maths — her three Major second places were commercial-tier results, not championship conversions. What survives is the 2026 Tokyo title: the violation attaches to a later race, and absent a finding of earlier use, prior results are not automatically annulled. The report does not state the disqualification scope.

Contrarian: the paper produced the sanction, not the drug

Under the noise there is a structure, and I wait for it to surface. Here the structure is this: four of the six years came from a forged document, not from a substance. Methylprednisolone has no proven endurance benefit — it reduces inflammation, masks pain, and shows up in an in-competition sample. When six years lands on a drug like that, it will be misread from both directions: some will call it AIU rigour, others will call it disproportionate enforcement against African road runners. Both readings skip the same thing — most of the weight came from the verification process, not the pharmacology.

The second angle points at the media. The frame is chosen before the story; documentary work taught me that. Choose the word "steroid" and the reader's mind assembles the S1 picture: strength-building, plainly dishonest. The S9 glucocorticoid picture is different — treatment, route, timing. That word error does damage downstream: once the world has read you as a steroid case, there is no room left to explain the timing of an injection — which closes the one defence the athlete actually had.

The third, and most useful, angle: the enforcement frontier has moved. The old question was whether the sample contained a drug. The new question is whether the document is real. The East African road-racing cases where an initial substance violation was compounded by a manufactured explanation are becoming a recognisable family. Aga belongs to it; she is not a one-off. And where a single informal medical network serves a single training cluster, the next instalment is already in the pipeline.

Looking ahead

Watch the date of the next case, not the next hearing. Six years is the number that will travel; the number that matters is how many athletes in that pipeline have a real doctor's phone number. A working version is not hard to describe: a credentialed physiotherapist on the payroll, a TUE file prepared before a knee injection, a washout schedule built backwards from the race calendar. Had any one of those existed, this article would not be getting written. Every empty lane still measures the runner who is not there — the question is how many of them had that number before they reached the lane.